Literature DB >> 3032970

Activation of the respiratory burst oxidase in a fully soluble system from human neutrophils.

J T Curnutte, R Kuver, B M Babior.   

Abstract

The O2(-)-forming respiratory burst oxidase is present in a dormant state in a fully soluble system containing both cytosol and a deoxycholate extract of membranes from resting human neutrophils. Sodium dodecyl sulfate at low concentrations converts this soluble dormant oxidase into its catalytically active form. The Vmax for the activated oxidase was 2.1 mumol of O2-/min/mg of membrane protein. Michaelis constants for NADPH and NADH (38 microM and 1.7 mM, respectively) were similar to those measured previously in other systems. Oxidase activity was not detected after sodium dodecyl sulfate treatment of systems containing solubilized neutrophil membranes obtained from patients with X-linked chronic granulomatous disease. These results suggest that the deoxycholate extract contains both the resting oxidase and those membrane-associated components needed for its activation, all in functioning states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032970

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Absolute requirement for GTP in activation of human neutrophil NADPH oxidase in a cell-free system: role of ATP in regenerating GTP.

Authors:  P Peveri; P G Heyworth; J T Curnutte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits.

Authors:  Susan M E Smith; Jaeki Min; Thota Ganesh; Becky Diebold; Tsukasa Kawahara; Yerun Zhu; James McCoy; Aiming Sun; James P Snyder; Haian Fu; Yuhong Du; Iestyn Lewis; J David Lambeth
Journal:  Chem Biol       Date:  2012-06-22

3.  Spontaneous activation of NADPH oxidase in a cell-free system: unexpected multiple effects of magnesium ion concentrations.

Authors:  A R Cross; R W Erickson; B A Ellis; J T Curnutte
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

4.  Cytosolic components of the respiratory burst oxidase: resolution of four components, two of which are missing in complementing types of chronic granulomatous disease.

Authors:  J T Curnutte; P J Scott; L A Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Chronic granulomatous disease due to a defect in the cytosolic factor required for nicotinamide adenine dinucleotide phosphate oxidase activation.

Authors:  J T Curnutte; R L Berkow; R L Roberts; S B Shurin; P J Scott
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 6.  Subcellular localization and dynamics of components of the respiratory burst oxidase.

Authors:  N Borregaard
Journal:  J Bioenerg Biomembr       Date:  1988-12       Impact factor: 2.945

7.  Superoxide generation is inhibited by phospholipase A2 inhibitors. Role for phospholipase A2 in the activation of the NADPH oxidase.

Authors:  L M Henderson; J B Chappell; O T Jones
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

8.  Impairment of raw 264.7 macrophage function by antiarrhythmic drugs.

Authors:  K C Das; H P Misra
Journal:  Mol Cell Biochem       Date:  1994-03-30       Impact factor: 3.396

9.  Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease.

Authors:  M C Dinauer; E A Pierce; R W Erickson; T J Muhlebach; H Messner; S H Orkin; R A Seger; J T Curnutte
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  Naphthalenesulphonamides block neutrophil superoxide production by intact cells and in a cell-free system: is myosin light chain kinase responsible for these effects?

Authors:  P G Heyworth; R W Erickson; J Ding; J T Curnutte; J A Badwey
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.